

UK JIA Biologics Register

2024: A YEAR IN REVIEW



35

NHS sites have
provided data



67

Participants
have been
recruited



793

Follow-ups
have been
submitted

4 PUBLICATIONS USING DATA FROM THE UK JIA BIOLOGICS REGISTER



**Switching from
originator to
biosimilar anti-
TNF?**

Children do just
as well as those
remaining on
the originator.



**First anti-TNF not
working?**

Children with
polyarticular JIA
do just as well on
a second anti-TNF
as those
switching to a
non-TNF biologic



**Treated with
methotrexate?**

Machine
learning finds
subgroups of
people who do
well



**Genetic risk
factors
(alongside
clinical
factors)**
found to help
identification of
uveitis in
patients with
JIA



Looking to 2025:

- **Recruitment of Tofacitinib** patients to the BCRD study remains a priority.
- **Recruitment of all other biologic, biosimilar and JAKi** (aside from etanercept/etanercept biosimilars) to BCRD Study continues.
- **Follow-up data collection** continues as per schedule.
- Participants who have reached **16 years of age + should be re-consented**, and consent form uploaded to the database.
- **Centre payments** will be processed Spring 2025 (BCRD) and Autumn 2025 (BSPAR).



THANK
you



[HTTPS://SITES.MANCHESTER.AC.UK/BCRDBSPAR/](https://sites.manchester.ac.uk/bcrdbspar/)
[HTTPS://X.COM/BCRD_STUDY](https://x.com/BCRD_STUDY)